Sections View Full Chapter Figures Tables Videos Annotate Full Chapter Figures Tables Videos Supplementary Content ++ See Chapter 35 (Gastroenterology). ++ Occurs in 1%–5% of newborns (platelet count <150,000/mm3); severe thrombocytopenia (<50,000/mm3) occurs in 0.1%–0.5%.Sick newborns have an incidence as high as 22%–50%. ++eFigure 37-1Graphic Jump LocationView Full Size||Download Slide (.ppt)Brief differential diagnosis for thrombocytopenia in neonates.*One of the most common causes of thrombocytopenia is improper specimen collection; confi rm with peripheral smear to exclude laboratory error +++ Immune Thrombocytopenias: Decreased Platelet Survival ++Table Graphic Jump Location|Download (.pdf)|PrintAutoimmune ThrombocytopeniaAlloimmune ThrombocytopeniaDefinitionAntibody made against maternal platelet antigen; antigen is also found on fetal plateletsAntibody made against paternal platelet antigen; antigen is also found on fetal plateletsClinical findingsMild to moderate thrombocytopenia (20,000–50,000/mm3)Petechiae and bruising are commonMother usually has thrombocytopenia or history of ITPMaternal platelets may be normal because she may have adequate production of platelets to compensate for increased destructionMay lead to severe thrombocytopenia (<20,000/mm3) and in utero hemorrhagic complications (∼20% of infants with NAIT have intracranial hemorrhages)Infant appears healthy but may have petechiae and bruisingMaternal platelet count is usually normalMost common antigen is HPA-1PathophysiologyMaternal autoantibodies cross the placenta and bind to neonatal platelets, causing increased destructionMaternal alloantibodies cross the placenta and bind to neonatal platelets, causing increased destructionDiagnosisIdentification of autoantibody in maternal serum against antigens on her own plateletsIdentification of alloantibody using paternal platelets and maternal serumPrenatal managementUse of steroids to prevent fetal thrombocytopenia is controversial; not shown to be of benefitUse of immune globulin to prevent fetal thrombocytopenia is controversial; not shown to be of benefitPUBS (Percutaneous Umbilical cord Blood Sampling) seems to be safe but is invasive, and its use is controversial; not shown to be of benefitMode of delivery (cesarean section vs vaginal) does not change maternal or fetal outcomes; cesarean section is not shown to be of benefitUse of steroids, immune globulin, PUBS, fetal scalp platelet counts during labor, and elective cesarean delivery can be used on a case-by-case basisPostnatal managementMay include platelet transfusions (pooled donor), steroids, immune globulin or exchange transfusionTransfuse platelets for levels <20,000/mm3 or for clinical bleedingIf diagnosis is made before delivery, maternal platelets are collected 24 h before deliveryIf infant requires platelet transfusions postnatally, use collected maternal platelets that have been washed and resuspended in plasmaIf emergent transfusion is required and maternal platelets are not available, either maternal whole blood or HPA-1–negative donor platelets may be usedImmune globulin at a dose of 1–2 g/kg total given over 2–3 h for 2–5 d has been reported with some successSteroids can be considered for persistent thrombocytopenia +++ Other Causes of Thrombocytopenia with Decreased Platelet Survival ++Table Graphic Jump Location|Download (.pdf)|PrintMechanismConditionTherapyPlatelet ... Your Access profile is currently affiliated with [InstitutionA] and is in the process of switching affiliations to [InstitutionB]. Please select how you would like to proceed. Keep the current affiliation with [InstitutionA] and continue with the Access profile sign in process Switch affiliation to [InstitutionB] and continue with the Access profile sign in process Get Free Access Through Your Institution Learn how to see if your library subscribes to McGraw Hill Medical products. Subscribe: Institutional or Individual Sign In Error: Incorrect UserName or Password Username Error: Please enter User Name Password Error: Please enter Password Sign in Forgot Password? Forgot Username? Download the Access App: iOS | Android Sign in via OpenAthens Sign in via Shibboleth You already have access! Please proceed to your institution's subscription. Create a free profile for additional features.